Symbols

BTAI

Bioxcel Therapeutics·NASDAQ

--(--)

BTAI Profile

Bioxcel Therapeutics, Inc.

A biopharmaceutical company developing novel therapeutics for neuroscience and immuno-oncology disorders

Industry

Pharmaceutical

Established Date

03/29/2017

Listing Date

03/08/2018

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.bioxceltherapeutics.com

Security Type

Common stock

Office address

555 Long Wharf Drive New Haven CT 06511

Business

Introduction

Bioxcel Therapeutics, Inc., a Delaware corporation, was incorporated on March 29, 2017 and is a wholly-owned subsidiary of BioXcel. The company is a biopharmaceutical company that leverages artificial intelligence platforms to develop transformative drugs in neuroscience. Its commercial product IGALMI has been approved for the treatment of acute agitation associated with schizophrenia and bipolar disorder, and its R&D pipeline includes drug candidates for agitation of Alzheimer's disease and immuno-oncology assets.